The present study aimed to evaluate a panel of 8 HLA-G 3′UTR polymorphisms and determine their effects on the risk of G3-4 cumulative toxicity related to adjuvant folinic acid/5-fluorouracil/oxaliplatin-based (FOLFOX4-based) therapy in 144 patients with non-metastatic CRC. Here, HLA-G is linked to colorectal carcinoma.